5 completed, 5 recruiting, 2 active not recruiting, 2 terminated. 11 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Recruiting 3, Terminated 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Stage II Bladder Cancer AJCC v8: new trials by email Literature Review of Stage II Bladder Cancer AJCC v8 trials Research Report on Stage II Bladder Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial Non-Interventional Study - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Recruiting | OHSU Knight Cancer Institute | 100 | 2026-06-29 | 2026-08-14 | |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-10-30 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 47 | 2025-03-31 | 2026-10-01 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-12 | 2025-10-21 | |
| Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan - Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Terminated | University of Washington | 4 | 2023-06-15 | 2026-04-27 |
| Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Terminated | SWOG Cancer Research Network | 6 | 2022-08-10 | 2024-12-30 |
| Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer Cisplatin, Doxorubicin, Methotrexate - Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | Phase 2 | Completed | University of Washington | 17 | 2020-11-24 | 2025-09-18 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Completed | City of Hope Medical Center | 22 | 2020-08-11 | 2026-10-14 | |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Atezolizumab, Biopsy of Bladder, Cisplatin - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 475 | 2019-06-03 | 2026-08-28 |
| Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study Non-Interventional Study - Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 | Active not recruiting | Mayo Clinic | 204 | 2018-10-12 | 2026-04-17 | |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy Pembrolizumab - Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2018-01-11 | 2024-06-25 |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
Urinary Bladder Neoplasms (16) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Urogenital Neoplasms (1) · Uterine Cervical Neoplasms (1)
Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Male Urogenital Diseases (16) · Neoplasms by Site (16) · Urinary Bladder Diseases (16) · Urogenital Diseases (16) · Urologic Diseases (16) · Urologic Neoplasms (16) · Neoplasms (15) · Urogenital Neoplasms (15) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Ureteral Diseases (2) · Urethral Diseases (2)
Magnetic Resonance Spectroscopy (7) · Cisplatin (5) · Platinum (5) · 1,2-diaminocyclohexaneplatinum II citrate (4) · Cystectomy (4) · Cystoscopy (4) · Gemcitabine (4) · Radiation (4) · Specimen Handling (4) · pembrolizumab (4) · Fluorouracil (3) · Mitomycin (3) · Mitozytrex (3) · Transurethral Resection of Bladder (3) · dehydroftorafur (3)
National Cancer Institute (NCI) (3) · University of Washington (3) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · City of Hope Medical Center (1) · NRG Oncology (1) · OHSU Knight Cancer Institute (1) · SWOG Cancer Research Network (1) · University of California, San Francisco (1) · Yuanquan Yang (1)
United States (15) · Canada (1)
Parminder Singh (2) · Petros Grivas (2) · Arlene Siefker-Radtke (1) · Di Maria Jiang (1) · Jen-Jane Liu (1) · Jonathan Wright, MD (1) · Laleh Melstrom (1) · Leslie Ballas (1) · Mark D. Tyson, M.D., M.P.H. (1) · Neema Navai (1) · Scott E Delacroix (1) · Vadim Koshkin, MD (1) · Yuanquan Yang, MD, PhD (1)
U10CA180888 (2), P30CA016672 (1), P30CA033572 (1), U10CA180868 (1), UM1CA186644 (1)